3 LOCHSIDE WAY, EDINBURGH, X0
Holds Annual General Meeting on June 8, 2026
Appoints Ian Webster as Chief Financial Officer
Reports First Quarter 2026 Financial Results and Provides Business Update
A New Era in Oncology For the Year Ended 31 December 2025 Annual Report
Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
Appoints Theresa Bruce as Chief Operating Officer
Hugh S. Griffith Returns as CEO
Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities of Certain Foreign Private Issuers
No filings found
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Post-Effective Amendment to a Registration Statement for Depositary Shares
Correspondence
Submission Upload